GenSight Biologics Reports Long-Term Results for LUMEVOQ®

GenSight Biologics announces five-year clinical results for its LUMEVOQ® product for the treatment of Leber Hereditary Optic Neuropathy (LHON). In the RESTORE study, patients demonstrated significant bilateral improvement in visual acuity and good tolerability.

These results, published in JAMA Ophthalmology, confirm the benefits already observed in the RESCUE and REVERSE studies, and provide strong evidence of the benefit-risk ratio of LUMEVOQ® for the MT-ND4 genetic mutation.

After five years, treated patients showed an average increase of 22 ETDRS letters for treated eyes and 20 letters for sham-injected eyes. A majority of participants also reported a significant improvement in quality of life scores.